A detailed history of Geode Capital Management, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Geode Capital Management, LLC holds 4,837,985 shares of BCRX stock, worth $36.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,837,985
Previous 4,710,277 2.71%
Holding current value
$36.6 Million
Previous $29.1 Million 26.31%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$6.41 - $8.69 $818,608 - $1.11 Million
127,708 Added 2.71%
4,837,985 $36.8 Million
Q2 2024

Aug 09, 2024

BUY
$4.13 - $6.79 $1.28 Million - $2.1 Million
310,006 Added 7.05%
4,710,277 $29.1 Million
Q1 2024

May 13, 2024

BUY
$4.89 - $7.65 $682,805 - $1.07 Million
139,633 Added 3.28%
4,400,271 $22.4 Million
Q4 2023

Feb 13, 2024

BUY
$4.98 - $6.77 $1.74 Million - $2.37 Million
349,561 Added 8.94%
4,260,638 $25.5 Million
Q3 2023

Nov 13, 2023

BUY
$6.71 - $7.92 $526,882 - $621,894
78,522 Added 2.05%
3,911,077 $27.7 Million
Q2 2023

Aug 11, 2023

BUY
$6.96 - $8.81 $1.25 Million - $1.58 Million
178,999 Added 4.9%
3,832,555 $27 Million
Q1 2023

May 15, 2023

BUY
$7.94 - $11.84 $1.48 Million - $2.21 Million
187,006 Added 5.39%
3,653,556 $30.5 Million
Q4 2022

Feb 13, 2023

BUY
$10.5 - $14.2 $1.06 Million - $1.43 Million
100,706 Added 2.99%
3,466,550 $39.8 Million
Q3 2022

Nov 14, 2022

BUY
$10.79 - $14.81 $902,982 - $1.24 Million
83,687 Added 2.55%
3,365,844 $42.4 Million
Q2 2022

Aug 12, 2022

BUY
$7.89 - $17.88 $1,412 - $3,200
179 Added 0.01%
3,282,157 $34.7 Million
Q1 2022

May 13, 2022

BUY
$11.56 - $19.76 $734,083 - $1.25 Million
63,502 Added 1.97%
3,281,978 $53.4 Million
Q4 2021

Feb 11, 2022

BUY
$11.18 - $15.46 $882,962 - $1.22 Million
78,977 Added 2.52%
3,218,476 $44.6 Million
Q3 2021

Nov 12, 2021

BUY
$14.21 - $17.65 $382,774 - $475,438
26,937 Added 0.87%
3,139,499 $45.1 Million
Q2 2021

Aug 13, 2021

BUY
$9.5 - $17.24 $1.16 Million - $2.1 Million
122,039 Added 4.08%
3,112,562 $49.2 Million
Q1 2021

May 12, 2021

BUY
$7.37 - $13.61 $2.46 Million - $4.55 Million
334,394 Added 12.59%
2,990,523 $30.4 Million
Q4 2020

Feb 12, 2021

BUY
$3.37 - $8.61 $715,845 - $1.83 Million
212,417 Added 8.69%
2,656,129 $19.8 Million
Q3 2020

Nov 13, 2020

BUY
$3.43 - $5.53 $799,049 - $1.29 Million
232,959 Added 10.54%
2,443,712 $8.39 Million
Q2 2020

Aug 13, 2020

BUY
$1.9 - $5.61 $13,442 - $39,690
7,075 Added 0.32%
2,210,753 $10.5 Million
Q1 2020

May 14, 2020

BUY
$1.6 - $4.11 $469,238 - $1.21 Million
293,274 Added 15.35%
2,203,678 $4.41 Million
Q4 2019

Feb 13, 2020

BUY
$1.59 - $3.45 $678,996 - $1.47 Million
427,042 Added 28.79%
1,910,404 $6.59 Million
Q3 2019

Nov 12, 2019

SELL
$2.5 - $3.73 $8,092 - $12,074
-3,237 Reduced 0.22%
1,483,362 $4.25 Million
Q2 2019

Aug 14, 2019

BUY
$2.91 - $9.15 $471,681 - $1.48 Million
162,090 Added 12.24%
1,486,599 $5.63 Million
Q1 2019

May 14, 2019

BUY
$7.38 - $9.72 $713,985 - $940,371
96,746 Added 7.88%
1,324,509 $10.8 Million
Q4 2018

Feb 13, 2019

BUY
$6.51 - $9.6 $708,190 - $1.04 Million
108,785 Added 9.72%
1,227,763 $9.91 Million
Q3 2018

Nov 13, 2018

BUY
$5.52 - $7.99 $637,460 - $922,701
115,482 Added 11.51%
1,118,978 $8.54 Million
Q2 2018

Aug 14, 2018

BUY
$4.6 - $6.52 $578,887 - $820,509
125,845 Added 14.34%
1,003,496 $5.75 Million
Q1 2018

May 15, 2018

BUY
$4.35 - $5.82 $253,326 - $338,933
58,236 Added 7.11%
877,651 $4.19 Million
Q4 2017

Feb 13, 2018

BUY
$4.16 - $5.33 $298,126 - $381,974
71,665 Added 9.58%
819,415 $4.02 Million
Q3 2017

Nov 14, 2017

BUY
$4.1 - $5.97 $381,980 - $556,201
93,166 Added 14.23%
747,750 $3.92 Million
Q2 2017

Aug 14, 2017

BUY
N/A
654,584
654,584 $3.64 Million

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.